$3.010
-0.115 (-3.83%)收盘时
CUPR 资讯
CUPR 事件
R. F. Lafferty & Co. Acts as Underwriter
R. F. Lafferty & Co. is acting as the underwriter for the offering.
Cuprina Holdings Receives FDA Clearance for Medifly Maggots
Cuprina Holdings announced that an indirectly wholly-owned subsidiary of the company, Cuprina Pte. has received 510 clearance from the FDA for Medifly Maggots, its medical-grade Lucilia cuprina larvae used in maggot debridement therapy.
Cuprina Holdings Completes Reverse Stock Split, Requests Nasdaq Hearing
Cuprina Holdings announced that it completed a reverse stock split on May 27, 2026, and requested a hearing before the Nasdaq Hearings Panel, in response to a staff determination letter received on May 27, 2026, from the Listing Qualifications Department of the Nasdaq Stock Market LLC. The Letter notified the company that, due to the company's failure to regain compliance with a minimum bid price of $1.00 per share requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2), Nasdaq has determined that company's securities will be scheduled for delisting from Nasdaq unless the company requests an appeal of the Determination to a Panel. On November 26, 2025, the company received a notice from Nasdaq, notifying the company that based upon the closing bid price of its securities for the last 30 consecutive business days preceding the Notice, the company was not in compliance with the Minimum Bid Requirement. In accordance with Listing Rule 5810(c)(3)(a), the Notice provided the company a period of 180 calendar days from the date of the Notice, or until May 26, 2026, to regain compliance with the Minimum Bid Requirement. According to the Letter, the company had not regained compliance with the Minimum Bid Requirement as of May 26, 2026. Unless the company requests an appeal of the Determination by June 3, 2026 to the Panel, the company's securities will be suspended at the opening of business on June 5, 2026, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission, which will remove the company's securities from listing and registration on Nasdaq. The company has proactively completed the share consolidation on May 27, 2026, which is expected to bring the company's bid price into compliance with the Minimum Bid Requirement. The company remains committed to maintaining its Nasdaq listing and will provide its shareholders with material updates when they are available.
Cuprina Holdings Implements 1-for-8 Share Consolidation
Cuprina Holdings announced that it plans to implement a 1-for-8 share consolidation of its Class A ordinary shares and Class B ordinary shares, effective on or around May 27. Beginning with the opening of trading on or around May 27, the company's Class A shares will begin trading on a post-share consolidation basis on the Nasdaq Capital Market under the same symbol " CUPR ", but under a new CUSIP number of G2592E110. "This action is an important step toward maintaining our Nasdaq listing and enhancing the Company's long-term financial flexibility. This approval reflects our shareholders' support for strengthening Cuprina's capital markets position as we continue advancing our biomedical and collagen-based technology portfolio," said Cuprina Chief Executive Officer David Quek.
Cuprina Holdings Receives MEDIFLY Product Classification in Saudi Arabia
Cuprina Holdings announced several strategic business developments, including a significant regulatory classification in Saudi Arabia and the expansion of its Medical and Scientific Advisory Board. Cuprina's 49%-owned associate, Cuprina MENA Co. Ltd, has received official product classification from the Saudi Food and Drug Authority for MEDIFLY, the Company's medical-grade maggot debridement therapy. The SFDA has classified MEDIFLY as a Medical Device-Drug combination product, with the primary mode of action regulated under the medical device framework. This classification, which allows the Company to finalize the scientific and technical requirements necessary for the commercial distribution of MEDIFLY across Saudi Arabia's healthcare network, is a critical milestone in Cuprina's expansion strategy for the Middle East and North Africa region. The Company is also pleased to announce the appointment of Enming Yong to its Medical and Scientific Advisory Board. Dr. Yong is a highly respected Consultant in the Department of Endocrinology at Tan Tock Seng Hospital and serves as an Adjunct Senior Lecturer at the Lee Kong Chian School of Medicine, both located in Singapore.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。